Suzhou Junjing BioSciences Co., Ltd.
7
1
2
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
57.1%
4 terminated/withdrawn out of 7 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis
Role: lead
A Study of WJ05129 in Advanced Malignant Solid Tumors
Role: lead
A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer
Role: lead
The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer
Role: lead
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
Role: lead
A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors
Role: lead
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
Role: lead
All 7 trials loaded